Neurocognitive effects of aripiprazole in adolescents and young adults with bipolar disorder

Nordic Journal of Psychiatry

Volumn 66, Issue 4, 2012, Pages 276-282

  Wang, Liang Jen ^a,b   Yeh, Chin Bin ^c   Huang, Yu Shu ^a,b   Tang, Ching Shu ^d   Chou, Wen Jiun ^d   Chou, Miao Chun ^d   Chen, Chih Ken ^a,b,e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Antipsychotics; Attention; Executive function; Mood disorder

Indexed keywords

ARIPIPRAZOLE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DSM-IV; FEMALE; HUMAN; MALE; MANIA; MIXED MANIA AND DEPRESSION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; SCORING SYSTEM;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRIEF PSYCHIATRIC RATING SCALE; COGNITION; COGNITION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; PIPERAZINES; PROSPECTIVE STUDIES; QUINOLONES; SEVERITY OF ILLNESS INDEX; TAIWAN; YOUNG ADULT;

EID: 84865852168     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039488.2011.643484     Document Type: Article

References (45)

1. Post RM. The impact of bipolar depression. J Clin Psychiatry 2005;66 Suppl 5:5-10.
2. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: A systematic review of cross-sectional evidence. Bipolar Disord 2006;8:103-16.
3. Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004;161:262-70.
4. Basso MR, Lowery N, Neel J, Purdie R, Bornstein RA. Neuropsychological impairment among manic, depressed, and mixed-episode inpatients with bipolar disorder. Neuropsychology 2002;16:84-91.
5. Malhi GS, Ivanovski B, Hadzi-Pavlovic D, Mitchell PB, Vieta E, Sachdev P. Neuropsychological defi cits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord 2007;9:114-25.
6. Blader JC, Carlson GA. Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996-2004. Biol Psychiatry 2007;62:107-14.
7. Doyle AE, Wilens TE, Kwon A, Seidman LJ, Faraone SV, Fried R, et al. Neuropsychological functioning in youth with bipolar disorder. Biol Psychiatry 2005;58:540-8.
8. Joseph MF, Frazier TW, Youngstrom EA, Soares JC. A quantitative and qualitative review of neurocognitive performance in pediatric bipolar disorder. J Child Adolesc Psychopharmacol 2008;18:595-605.
9. Pavuluri MN, O'Connor MM, Harral EM, Moss M, Sweeney JA. Impact of neurocognitive function on academic diffi culties in pediatric bipolar disorder: A clinical translation. Biol Psychiatry
10. Sala R, Axelson D, Birmaher B. Phenomenology, longitudinal course, and outcome of children and adolescents with bipolar spectrum disorders. Child Adolesc Psychiatr Clin N Am 2009;18:273-89, vi.i.
11. Gupta S, Masand P. Aripiprazole: Review of its pharmacology and therapeutic use in psychiatric disorders. Ann Clin Psychiatry 2004;16:155-66.
12. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo-and lithium-controlled study. J Affect Disord 2009;112:36-49.
13. Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: Recent progress. CNS Drugs 2010;24:575-93.
14. Biederman J, McDonnell MA, Wozniak J, Spencer T, Aleardi M, Falzone R, et al. Aripiprazole in the treatment of pediatric bipolar disorder: A systematic chart review. CNS Spectr 2005;10:141-8.
15. Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: A randomized, doubleblind, placebo-controlled study. J Clin Psychiatry 2009;70:1441-51.
16. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. The neurocognitive effects of aripiprazole: An open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187:312-20.
17. Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol 2011 May 26. [Epub ahead of print].
18. Carli M, Calcagno E, Mainolfi P, Mainini E, Invernizzi RW. Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive defi cit of schizophrenia in rats: Relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology (Berl) 2011;214:639-52.
19. Tang CS, Yeh CB, Huang YS, Wang LJ, Chou WJ, Chou MC, et al. Long-term effectiveness of aripiprazole in adolescents and young adults with bipolar disorder: A naturalistic study. Int J Psychiatry Clin Pract 2010;14:252-6.
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. APA: Washington, DC; 2000.
21. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59 Suppl 20:22-33;quiz 34-57.
22. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry 2005;187:366-71.
23. Conners CK. The computerized Continuous Performance Test. Psychopharmacol Bull 1985;21:891-2.
24. Conners CK. Conners' Continuous Performance Test II (CPTII) for Windows. Technical guide and software manual. New York: MHS; 2004.
25. Chen KC, Chu CL, Yang YK, Yeh TL, Lee IH, Chen PS, et al. The relationship among insight, cognitive function of patients with schizophrenia and their relatives'perception. Psychiatry Clin Neurosci 2005;59:657-60.
26. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual. Psychological Assessment Resources: Odessa; 1993.
27. Holmes MK, Erickson K, Luckenbaugh DA, Drevets WC, Bain EE, Cannon DM, et al. A comparison of cognitive functioning in medicated and unmedicated subjects with bipolar depression. Bipolar Disord 2008;10:806-15.
28. Ghaemi SN, Gilmer WS, Dunn RT, Hanlon RE, Kemp DE, Bauer AD, et al. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol 2009;29:291-5.
29. Kaye NS, Graham J, Roberts J, Thompson T, Nanry K. Effect of open-label lamotrigine as monotherapy and adjunctive therapy on the self-assessed cognitive function scores of patients with bipolar I disorder. J Clin Psychopharmacol 2007;27:387-91.
30. Li Z, Ichikawa J, Dai J, Meltzer HY. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol 2004;493:75-83.
31. Sax KW, Strakowski SM, Zimmerman ME, DelBello MP, Keck PE, Jr., Hawkins JM. Frontosubcortical neuroanatomy and the Continuous Performance Test in mania. Am J Psychiatry 1999;156:139-41.
32. Altshuler LL, Ventura J, van Gorp WG, Green MF, Theberge DC, Mintz J. Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia and normal control subjects. Biol Psychiatry 2004;56:560-9.
33. Fleck DE, Shear PK, Madore M, Strakowski SM. Wisconsin Card Sorting Test performance in bipolar disorder: Effects of mood state and early course. Bipolar Disord 2008;10:539-45.
34. Meyer SE, Carlson GA, Wiggs EA, Martinez PE, Ronsaville DS, Klimes-Dougan B, et al. A prospective study of the association among impaired executive functioning, childhood attentional problems, and the development of bipolar disorder. Dev Psychopathol 2004;16:461-76.
35. Frangou S, Haldane M, Roddy D, Kumari V. Evidence for defi cit in tasks of ventral, but not dorsal, prefrontal executive function as an endophenotypic marker for bipolar disorder. Biol Psychiatry 2005;58:838-9.
36. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-11.
37. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274:329-36.
38. Ichikawa J, Dai J, O' Laughlin IA, Fowler WL, Meltzer HY. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002;26:325-39.
39. Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Parker CR, Jr., Weissenburger JE, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996;57:470-84.
40. Henin A, Mick E, Biederman J, Fried R, Wozniak J, Faraone SV, et al. Can bipolar disorder-specifi c neuropsychological impairments in children be identifi ed? J Consult Clin Psychol 2007;75:210-20.
41. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.
42. Dell'Osso L, Pini S, Cassano GB, Mastrocinque C, Seckinger RA, Saettoni M, et al. Insight into illness in patients with mania, mixed mania, bipolar depression and major depression with psychotic features. Bipolar Disord 2002;4:315-22.
43. Basso MR, Lowery N, Ghormley C, Bornstein RA. Practice effects on the Wisconsin Card Sorting Test-64 Card version across 12 months. Clin Neuropsychol 2001;15:471-8.
44. Maassen GH, Bossema E, Brand N. Reliable change and practice effects: Outcomes of various indices compared. J Clin Exp Neuropsychol 2009;31:339-52.
45. McCaffrey RJ, Westervelt HJ. Issues associated with repeated neuropsychological assessments. Neuropsychol Rev 1995;5: 203-21.